NASDAQ: BOLTBolt Biotherapeutics Inc Stock
$1.11+0.00 (+0%)
Updated Apr 22, 2024
BOLT Price
$1.11
Fair Value Price
$1.47
Market Cap
$42.32M
52 Week Low
$0.84
52 Week High
$2.03
P/E
-0.61x
P/B
0.38x
P/S
5.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.88M
Earnings
-$69.20M
Gross Margin
100%
Operating Margin
-878.58%
Profit Margin
-878.6%
Debt to Equity
0.42
Operating Cash Flow
-$70M
Beta
0.94
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BOLT Overview
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company developing immuno-oncology agents to target tumor cells for elimination by the immune system.BDC-1001, a human epidermal growth factor receptor 2 (HER2), is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors. BDC-2034 is a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. BDC-3042 is a Dectin-2 agonist antibody program intended to repolarize critical cells in the tumor microenvironment. Bolt Biotherapeutics was incorporated in 2015 and is headquartered in Redwood City, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BOLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BOLT ($1.11) is undervalued by 24.3% relative to our estimate of its Fair Value price of $1.47 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BOLT ($1.11) is significantly undervalued by 24.3% relative to our estimate of its Fair Value price of $1.47 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BOLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BOLT due diligence checks available for Premium users.
Be the first to know about important BOLT news, forecast changes, insider trades & much more!
BOLT News
Valuation
BOLT fair value
Fair Value of BOLT stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$1.47
Undervalued by
24.30%
BOLT ($1.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BOLT ($1.11) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BOLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BOLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.61x
Industry
16.21x
Market
41x
BOLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
5.82x
BOLT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BOLT's financial health
Profit margin
Revenue
$2.1M
Net Income
-$17.9M
Profit Margin
-857%
BOLT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BOLT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$159.8M
Liabilities
$47.0M
Debt to equity
0.42
BOLT's short-term assets ($105.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BOLT's short-term assets ($105.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BOLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BOLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.3M
Investing
$15.8M
Financing
$106.0k
BOLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BOLT vs Biotech Stocks
Bolt Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.